当前位置: 首页 >> 检索结果
963. Inhibition of tumor cell kinetics and serum insulin growth factor I levels by octreotide in colorectal cancer patients.
作者: S Cascinu.;E Del Ferro.;C Grianti.;M Ligi.;R Ghiselli.;G Foglietti.;V Saba.;F Lungarotti.;G Catalano.
来源: Gastroenterology. 1997年113卷3期767-72页
Octreotide was shown to inhibit the growth of colon cancer and to reduce serum concentrations of tumor growth factors such as insulin-like growth factor I (IGF-I) and epidermal growth factor (EGF) in vitro and in animal models. Effects of octreotide on tumor cell kinetics and serum concentration of IGF-I and EGF in patients with colorectal cancer were evaluated.
964. Predictors of the efficacy of interferon therapy in chronic hepatitis C virus infection. Tokyo-Chiba Hepatitis Research Group.
作者: Y Shiratori.;N Kato.;O Yokosuka.;F Imazeki.;E Hashimoto.;N Hayashi.;A Nakamura.;M Asada.;H Kuroda.;N Tanaka.;Y Arakawa.;M Omata.
来源: Gastroenterology. 1997年113卷2期558-66页
The relative role of virus load and hepatitis C virus (HCV) subtype as predictor of the efficacy of interferon (IFN) therapy is still in dispute. To resolve this issue, a multicenter, randomized, prospective study of 272 patients with chronic hepatitis C but without cirrhosis was conducted.
965. A prospective randomized comparison between small bowel enteroclysis and small bowel follow-through in Crohn's disease.
作者: C N Bernstein.;I F Boult.;H M Greenberg.;W van der Putten.;G Duffy.;G R Grahame.
来源: Gastroenterology. 1997年113卷2期390-8页
Small bowel enteroclysis (SBE) has been suggested to be superior to the small bowel follow-through (SBFT) for diagnosing the presence and extent of Crohn's disease. The aim was to perform a prospective randomized study at a single university medical center comparing SBE with SBFT in patients with Crohn's disease.
966. Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease. Crohn's Disease Study Group.
Interleukin 10 (IL-10) is a cytokine with immunosuppressive and anti-inflammatory activities. Gene-targeted IL-10-deficient mice develop a chronic intestinal inflammatory disease that is reminiscent of Crohn's disease. The present double-blind randomized multicenter trial was designed to evaluate the safety, tolerance, and pharmacokinetics of IL-10 in Crohn's disease.
968. Treatment of biliary colic with diclofenac: a randomized, double-blind, placebo-controlled study.
作者: E A Akriviadis.;M Hatzigavriel.;D Kapnias.;J Kirimlidis.;A Markantas.;A Garyfallos.
来源: Gastroenterology. 1997年113卷1期225-31页
Nonsteroidal anti-inflammatory drugs (NSAIDs) have been used to relieve biliary colic. Follow-up was limited in previous studies, and the role of NSAIDs in the natural history of biliary colic has not been clarified. The purpose of this study was to evaluate the efficacy of diclofenac, a potent NSAID, in the the immediate symptomatic relief of biliary colic and the prevention of cholelithiasis-related complications.
969. Etidronate versus fluoride for treatment of osteopenia in primary biliary cirrhosis: preliminary results after 2 years.
作者: N Guañabens.;A Parés.;A Monegal.;P Peris.;F Pons.;L Alvarez.;M J de Osaba.;M Roca.;M Torra.;J Rodés.
来源: Gastroenterology. 1997年113卷1期219-24页
Because osteopenia increases morbidity of primary biliary cirrhosis (PBC), the effects of cyclical etidronate vs. sodium fluoride on bone mass were compared in patients with PBC.
970. Famotidine for healing and maintenance in nonsteroidal anti-inflammatory drug-associated gastroduodenal ulceration.
作者: N Hudson.;A S Taha.;R I Russell.;P Trye.;J Cottrell.;S G Mann.;A J Swanell.;R D Sturrock.;C J Hawkey.
来源: Gastroenterology. 1997年112卷6期1817-22页
Nonsteroidal anti-inflammatory drugs (NSAIDs) are strongly associated with gastroduodenal ulceration. How to manage patients with NSAID-associated ulcers is a common clinical dilemma. High-dose famotidine in the healing and maintenance of NSAID-associated gastroduodenal ulceration was therefore evaluated.
971. Safety and efficacy of repeated shockwave lithotripsy of gallstones with and without adjuvant bile acid therapy.
作者: G Sauter.;G A Kullak-Ublick.;R Schumacher.;J Janssen.;L Greiner.;B Brand.;E F Stange.;K Wengler.;H Lochs.;A Freytag.;A Wissing.;J Holl.;M Sackmann.;G Paumgartner.
来源: Gastroenterology. 1997年112卷5期1603-9页
The value of adjuvant bile acid dissolution therapy after extracorporeal shockwave lithotripsy (ESWL) of gallbladder stones is under debate. A double-blind, randomized, multicenter trial was conducted to determine the safety and efficacy of repeated ESWL with and without adjuvant bile acid therapy.
972. Peptide YY inhibition of prostaglandin-induced intestinal secretion is haloperidol-sensitive in humans.
作者: C Rozé.;C Molis.;F C Xiaomei.;A Ropert.;J Genève.;J P Galmiche.
来源: Gastroenterology. 1997年112卷5期1520-8页
It is uncertain whether peptide YY (PYY) inhibits human intestinal secretion directly through enterocyte receptors or via indirect neural mechanisms. Thus, the effect of PYY on prostaglandin E2 (PGE2)-induced jejunal secretion in normal volunteers was measured, and it was determined whether a dopamine and sigma antagonist affected PYY effect.
974. Effects of ethanol consumption on hepatic hemodynamics in patients with alcoholic cirrhosis.
作者: A Luca.;J C García-Pagán.;J Bosch.;F Feu.;J Caballería.;R J Groszmann.;J Rodés.
来源: Gastroenterology. 1997年112卷4期1284-9页
Increased portal blood flow represents a compensatory mechanism preventing hepatic hypoxia after ethanol consumption. In addition, alcohol increases hepatic vascular resistance. Thus, ethanol consumption, by increasing hepatic vascular resistance and portal flow, may worsen portal hypertension in patients with cirrhosis. The aim of this study was to investigate the effects of ethanol consumption on hepatic hemodynamics in patients with alcohol-induced cirrhosis.
975. A randomized, placebo-controlled, double-blind trial of mesalamine in the maintenance of remission of Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group.
作者: L R Sutherland.;F Martin.;R J Bailey.;R N Fedorak.;M Poleski.;C Dallaire.;R Rossman.;F Saibil.;L Lariviere.
来源: Gastroenterology. 1997年112卷4期1069-77页
The efficacy of mesalamine for the maintenance of remission in patients with Crohn's disease is controversial. The aim of this study was to conduct a double-blind, placebo-controlled study of mesalamine (750 mg four times a day for 48 weeks) in maintaining remission in 293 patients with Crohn's disease. Patients were stratified according to the method of induction of remission (medical or surgical).
976. Leukotrienes in ulcerative colitis: results of a multicenter trial of a leukotriene biosynthesis inhibitor, MK-591.
作者: W G Roberts.;T J Simon.;R G Berlin.;R C Haggitt.;E S Snyder.;W F Stenson.;S B Hanauer.;J E Reagan.;A Cagliola.;W K Tanaka.;S Simon.;M L Berger.
来源: Gastroenterology. 1997年112卷3期725-32页
Leukotrienes (LTs) are believed to be important in the pathogenesis of ulcerative colitis (UC). The aim of this study was to determine whether inhibition of LT biosynthesis with a 5-lipoxygenase inhibitor (MK-591) induces remission in patients with mild to moderate UC.
977. A trial of zileuton versus mesalazine or placebo in the maintenance of remission of ulcerative colitis. The European Zileuton Study Group For Ulcerative Colitis.
作者: C J Hawkey.;L M Dube.;L V Rountree.;P J Linnen.;J F Lancaster.
来源: Gastroenterology. 1997年112卷3期718-24页
Leukotriene B4 is a major neutrophil chemoattractant detected during relapse of inflammatory bowel disease and represents a potentional therapeutic target. The aim of this study was to compare the efficacy of zileuton, an active 5-lipoxygenase inhibitor, with mesalazine and placebo in the maintenance of remission in ulcerative colitis.
979. Colonoscopic miss rates of adenomas determined by back-to-back colonoscopies.
作者: D K Rex.;C S Cutler.;G T Lemmel.;E Y Rahmani.;D W Clark.;D J Helper.;G A Lehman.;D G Mark.
来源: Gastroenterology. 1997年112卷1期24-8页
The miss rate of colonoscopy for neoplasms is poorly understood. The aim of this study was to determine the miss rate of colonoscopy by same day back-to-back colonoscopy.
980. Controlled trial of botulinum toxin injection versus placebo and pneumatic dilation in achalasia.
作者: V Annese.;M Basciani.;F Perri.;G Lombardi.;V Frusciante.;P Simone.;A Andriulli.;G Vantrappen.
来源: Gastroenterology. 1996年111卷6期1418-24页
Intrasphincteric injection of botulinum toxin has been suggested as an alternative treatment modality in esophageal achalasia. A controlled trial comparing botulinum toxin, placebo, and pneumatic dilation is reported.
|